Ponatinib use in two pediatric patients with relapsed Ph + ALL with ABL1 kinase domain mutations

Pediatr Hematol Oncol. 2019 Nov;36(8):514-519. doi: 10.1080/08880018.2019.1656685. Epub 2019 Sep 11.

Authors

Stephanie E Gruner¹, Hadi Sayeed², Lizmery Suarez-Ferguson², Cintia Perez², Rayne Rouce^{1

3}, Kevin E Fisher^{1

2}, Rachel E Rau¹

Affiliations

¹ Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
² Department of Pathology & Immunology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
³ Center for Cell and Gene Therapy, Texas Children's Hospital, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX, USA.

PMID: 31510844
DOI: 10.1080/08880018.2019.1656685

No abstract available

Keywords: BCR/ABL1 kinase point mutation analysis; Ponatinib; T315I mutation; pediatric; relapsed Ph + ALL.

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Female
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use*
Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Pyridazines / pharmacology
Pyridazines / therapeutic use*
Recurrence

Substances

Imidazoles
Pyridazines
ponatinib